Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1988 Dec;82(6):1901–1907. doi: 10.1172/JCI113808

Oligonucleotide linked to human gammaglobulin specifically diminishes anti-DNA antibody formation in cultured lymphoid cells from patients with systemic lupus erythematosus.

Y Borel 1, H Borel 1
PMCID: PMC442770  PMID: 2461963

Abstract

In vitro studies were undertaken to determine whether the level of anti-DNA antibody can be modulated in humans with systemic lupus erythematosus (SLE). DNA fragments of different sizes, i.e., oligonucleotide (N20-30) or oligonucleotide (N10-100), were covalently linked either to human gammaglobulin (HGG) and used as tolerogens or to keyhole limpet hemocyanin and used as immunogens. Experiments were done to determine whether such tolerogens specifically diminish antibodies to denatured DNA, native DNA, or both. PBL were obtained from 87 patients with SLE, 55 of whom spontaneously produced anti-DNA antibodies in vitro. Furthermore, of these 55 test subjects 23 made anti-DNA antibodies in response to antigen challenge in vitro. Exposure of PBL to tolerogenic oligonucleotide-HGG reduced spontaneous antibody formation in 34 of the 55 patients' PBL and abrogated the in vitro-induced response in all instances. The suppression was tolerogen specific. In some SLE patients lymphoid cells were suppressed by both (N10-100)-HGG and (N20-30)-HGG, while in others lymphoid cells were suppressed by only one. Longitudinal studies of spontaneous antibody production showed that the same tolerogens consistently reduced anti-DNA antibody formation in lymphoid cells of 12 patients on several occasions over a 2-yr interval, but in 8 others the results were either variable or inconsistent. In contrast, tolerogens consistently abrogated the antigen-induced response in all 23 patients' PBL. These results obtained in humans in vitro suggest that the principle of carrier-determined tolerance could be applied as a specific therapy for SLE in vivo.

Full text

PDF
1901

Images in this article

1904Image
on p.1904
1904Image
on p.1904
1905Image
on p.1905
1905Image
on p.1905
1906Image
on p.1906

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ando D. G., Sercarz E. E., Hahn B. H. Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model. J Immunol. 1987 May 15;138(10):3185–3190. [PubMed] [Google Scholar]
  2. André-Schwartz J., Datta S. K., Shoenfeld Y., Isenberg D. A., Stollar B. D., Schwartz R. S. Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clin Immunol Immunopathol. 1984 May;31(2):261–271. doi: 10.1016/0090-1229(84)90246-0. [DOI] [PubMed] [Google Scholar]
  3. Bastian D., Borel H., Sasaki T., Steinberg A. D., Borel Y. Immune response to nucleic acid antigens and native DNA by human peripheral blood lymphocytes in vitro. J Immunol. 1985 Sep;135(3):1772–1777. [PubMed] [Google Scholar]
  4. Borel H., Bastian D., Cooper B., Borel Y. A possible new therapy of systemic lupus erythematosus (SLE). Ann N Y Acad Sci. 1986;475:296–306. doi: 10.1111/j.1749-6632.1986.tb20878.x. [DOI] [PubMed] [Google Scholar]
  5. Borel H., Sasaki T., Stollar D. B., Borel Y. Conjugation of DNA fragments to protein carriers by glutaraldehyde: immunogenicity of oligonucleotide-hemocyanin conjugates. J Immunol Methods. 1984 Mar 16;67(2):289–302. doi: 10.1016/0022-1759(84)90469-1. [DOI] [PubMed] [Google Scholar]
  6. Borel Y., Lewis R. M., Stollar B. D. Prevention of murine lupus nephritis by carrier-dependent induction of immunologic tolerance to denatured DNA. Science. 1973 Oct 5;182(4107):76–78. doi: 10.1126/science.182.4107.76. [DOI] [PubMed] [Google Scholar]
  7. Carroll P., Stafford D., Schwartz R. S., Stollar B. D. Murine monoclonal anti-DNA autoantibodies bind to endogenous bacteria. J Immunol. 1985 Aug;135(2):1086–1090. [PubMed] [Google Scholar]
  8. Emlen W., Pisetsky D. S., Taylor R. P. Antibodies to DNA. A perspective. Arthritis Rheum. 1986 Dec;29(12):1417–1426. doi: 10.1002/art.1780291201. [DOI] [PubMed] [Google Scholar]
  9. Eshhar Z., Benacerraf B., Katz D. H. Induction of tolerance to nucleic acid determinants by administration of a complex of nucleoside D-glutamic acid and D-lysine (D-GL). J Immunol. 1975 Feb;114(2 Pt 2):872–876. [PubMed] [Google Scholar]
  10. Geha R. S., Fruchter L., Borel Y. Hapten-specific T-cell unresponsiveness induced bybenzylpenicilloyl autologous gamma globulin conjugates in human lymphocyes in vitro. J Clin Invest. 1980 Jun;65(6):1509–1514. doi: 10.1172/JCI109816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jacob L., Lety M. A., Choquette D., Viard J. P., Jacob F., Louvard D., Bach J. F. Presence of antibodies against a cell-surface protein, cross-reactive with DNA, in systemic lupus erythematosus: a marker of the disease. Proc Natl Acad Sci U S A. 1987 May;84(9):2956–2959. doi: 10.1073/pnas.84.9.2956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jacob L., Tron F., Bach J. F., Louvard D. A monoclonal anti-DNA antibody also binds to cell-surface protein(s). Proc Natl Acad Sci U S A. 1984 Jun;81(12):3843–3845. doi: 10.1073/pnas.81.12.3843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Koffler D., Schur P. H., Kunkel H. G. Immunological studies concerning the nephritis of systemic lupus erythematosus. J Exp Med. 1967 Oct 1;126(4):607–624. doi: 10.1084/jem.126.4.607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lafer E. M., Rauch J., Andrzejewski C., Jr, Mudd D., Furie B., Furie B., Schwartz R. S., Stollar B. D. Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids. J Exp Med. 1981 Apr 1;153(4):897–909. doi: 10.1084/jem.153.4.897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lambert P. H., Dixon F. J. Pathogenesis of the glomerulonephritis of NZB/W mice. J Exp Med. 1968 Mar 1;127(3):507–522. doi: 10.1084/jem.127.3.507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Leung D. Y., Burns J. C., Newburger J. W., Geha R. S. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest. 1987 Feb;79(2):468–472. doi: 10.1172/JCI112835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Miller T. E., Lahita R. G., Zarro V. J., MacWilliam J., Koffler D. Clinical significance of anti-double-stranded DNA antibodies detected by a solid phase enzyme immunoassay. Arthritis Rheum. 1981 Apr;24(4):602–610. doi: 10.1002/art.1780240406. [DOI] [PubMed] [Google Scholar]
  18. Miniter M. F., Stollar B. D., Agnello V. Reassessment of the clinical significance of native DNA antibodies in systemic lupus erythematosus. Arthritis Rheum. 1979 Sep;22(9):959–968. doi: 10.1002/art.1780220903. [DOI] [PubMed] [Google Scholar]
  19. Morimoto C., Borel Y. Hapten-specific carrier-dependent tolerance induction in man in vitro. Cell Immunol. 1983 Dec;82(2):415–421. doi: 10.1016/0008-8749(83)90174-0. [DOI] [PubMed] [Google Scholar]
  20. Morimoto C., Steinberg A. D., Schlossman S. F., Borel Y. In vitro nucleoside specific immune response by lymphocytes from systemic lupus erythematosus. J Clin Invest. 1983 May;71(5):1402–1409. doi: 10.1172/JCI110893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Papalian M., Lafer E., Wong R., Stollar B. D. Reaction of systemic lupus erythematosus antinative DNA antibodies with native DNA fragments from 20 to 1,200 base pairs. J Clin Invest. 1980 Feb;65(2):469–477. doi: 10.1172/JCI109690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pincus T., Schur P. H., Rose J. A., Decker J. L., Talal N. Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Engl J Med. 1969 Sep 25;281(13):701–705. doi: 10.1056/NEJM196909252811304. [DOI] [PubMed] [Google Scholar]
  23. Pisetsky D. S., Hoch S. O., Klatt C. L., O'Donnell M. A., Keene J. D. Specificity and idiotypic analysis of a monoclonal anti-Sm antibody with anti-DNA activity. J Immunol. 1985 Dec;135(6):4080–4085. [PubMed] [Google Scholar]
  24. Rauch J., Tannenbaum H., Stollar B. D., Schwartz R. S. Monoclonal anti-cardiolipin antibodies bind to DNA. Eur J Immunol. 1984 Jun;14(6):529–534. doi: 10.1002/eji.1830140609. [DOI] [PubMed] [Google Scholar]
  25. Rothfield N. F., Stollar B. D. The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J Clin Invest. 1967 Nov;46(11):1785–1794. doi: 10.1172/JCI105669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rubin R. L., Balderas R. S., Tan E. M., Dixon F. J., Theofilopoulos A. N. Multiple autoantigen binding capabilities of mouse monoclonal antibodies selected for rheumatoid factor activity. J Exp Med. 1984 May 1;159(5):1429–1440. doi: 10.1084/jem.159.5.1429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sano H., Morimoto C. Isolation of DNA from DNA/anti-DNA antibody immune complexes in systemic lupus erythematosus. J Immunol. 1981 Feb;126(2):538–539. [PubMed] [Google Scholar]
  28. Sasaki T., Muryoi T., Takai O., Tamate E., Ono Y., Koide Y., Ishida N., Yoshinaga K. Selective elimination of anti-DNA antibody-producing cells by antiidiotypic antibody conjugated with neocarzinostatin. J Clin Invest. 1986 Apr;77(4):1382–1386. doi: 10.1172/JCI112444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Schwartz R. S., Stollar B. D. Origins of anti-DNA autoantibodies. J Clin Invest. 1985 Feb;75(2):321–327. doi: 10.1172/JCI111704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Shoenfeld Y., Rauch J., Massicotte H., Datta S. K., André-Schwartz J., Stollar B. D., Schwartz R. S. Polyspecificity of monoclonal lupus autoantibodies produced by human-human hybridomas. N Engl J Med. 1983 Feb 24;308(8):414–420. doi: 10.1056/NEJM198302243080802. [DOI] [PubMed] [Google Scholar]
  31. Stohl W. Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. J Immunol. 1986 Jun 15;136(12):4407–4413. [PubMed] [Google Scholar]
  32. Stollar B. D., Borel Y. Nucleoside specificity in the carrier IgG-dependent induction of tolerance. J Immunol. 1976 Oct;117(4):1308–1313. [PubMed] [Google Scholar]
  33. Stollar B. D., Borel Y. Nucleoside-specific tolerance suppresses anti-nucleoside antibody forming cells. Nature. 1977 May 12;267(5607):158–160. doi: 10.1038/267158a0. [DOI] [PubMed] [Google Scholar]
  34. Takeuchi T., Koide J., Hosono O., Amano K., Homma M., Masuho Y., Morimoto C., Takano M., Abe T. DNA-daunorubicin complexes specifically suppress in vitro spontaneous anti-DNA antibody production in lymphocytes of patients with systemic lupus erythematosus. Arthritis Rheum. 1986 Oct;29(10):1216–1222. doi: 10.1002/art.1780291006. [DOI] [PubMed] [Google Scholar]
  35. Tan E. M. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol. 1982;33:167–240. doi: 10.1016/s0065-2776(08)60836-6. [DOI] [PubMed] [Google Scholar]
  36. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  37. Tan E. M., Schur P. H., Carr R. I., Kunkel H. G. Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest. 1966 Nov;45(11):1732–1740. doi: 10.1172/JCI105479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Winfield J. B., Faiferman I., Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest. 1977 Jan;59(1):90–96. doi: 10.1172/JCI108626. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES